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This review describes the key steps and methods which are used to develop enzyme assays
suitable for high-throughput screening (HTS) applications. The goals of HTS enzyme assays are
deﬁned relative to lower-throughput bench top assays and important aspects which go into
constructing robust and sensitive enzyme assays are described. Methods that have been applied
to common enzyme classes are reviewed and pitfalls related to assay artifacts are discussed.
We also suggest a reporting format to describe the steps in HTS enzyme assays.
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Developing sensitive enzyme assays suitable for high-
throughput screening (HTS) requires identiﬁcation of rele-
vant enzyme and substrates forms, methods in puriﬁcation,
careful measurements of kinetic parameters, characteriza-
tion of co-factors, buffers, and choice of a detection
technology for the ﬁnal HTS assay. The desired mode of
action (e.g. allosteric, competitive, slow-binding inhibitors)
for active compounds should also be considered in the assay
development process. In the ﬁrst part of this review we
deﬁne the goals of an HTS enzyme assay and provide an
overview of the key steps in this process. In the second part
we give an overview of speciﬁc technologies that have been
employed to measure activity for various enzyme classes in
a high-throughput setting. As well, we discuss the critical
parameters that should be conveyed when reporting HTS
enzyme assay data.
In general, cell-free HTS assays for enzymes have been
developed using three main approaches (Figure 1). These
are (1) detection of substrate depletion, (2) detection of
product formation and (3) detecting direct binding of a
ligand to the enzyme. Methods for measuring the E  S
complex, although available for many years using fast
kinetic readers (Lobb and Auld, 1979), have not transitioned
into HTS. For some well-explored enzyme families such as
protein kinases all three methods are available and the
choice of which assay to use will depend on biases towards a
particular detection technology, reagent expense, the
amount of enzyme required and ease of implementation
within the laboratory. These considerations are discussed
below along with the goals of HTS enzyme assays.Goals of HTS enzyme assays
The goal of HTS assays is to provide sufﬁcient performance
to support the testing of millions of samples in a highly
reproducible manner, often over the course of multiple
enzyme preparations and multiple weeks of assay repeti-
tion. Therefore, high-throughput enzymatic assays for iden-
tiﬁcation of modulators must adhere to stringentrequirements that surpass those of traditional bench-top
activity assays. The components of the system must be
stable over the time course of the reaction, often up to
hours, and not deteriorate or otherwise be impacted by the
liquid dispensers or additional equipment employed for
automation. However, whether the assay is to be used for
bench top or HTS use, of central importance is obtaining a
fundamental understanding of the enzymology and bio-
chemistry of the target because this information dictates
the quality of the assay and the type of inhibitors that can
be identiﬁed by HTS.
Biochemical assay development begins with a puriﬁed or
semi-puriﬁed enzyme preparation that demonstrates catalytic
activity on a relevant substrate in a cell-free context. Often,
literature surrounding homologous enzymes or enzymes cata-
lyzing similar reactions can be used as a guide for setting up
initial activity assays, providing insight into initial test condi-
tions such as buffer and salt concentration, pH, cofactor
requirements, etc. From these preliminary experiments, many
parameters must be considered to ultimately achieve a robust
and sensitive assay suitable for use in compound screening and
drug discovery efforts. Of primary importance is determining
the Michaelis–Menten steady state kinetic parameters (Km and
kcat) of the enzyme for the substrate(s) consumed in the
reaction (Figure 2) (Copeland, 2003). The Michaelis–Menten
constants serve to anchor the assay among all of the variations
tested during assay optimization and are critical in the inter-
pretation of IC50s determined for inhibitors of the enzyme assay.
They can also help to elucidate the speciﬁc binding order of
substrates in multi-substrate reactions and provide a means to
compare the activity of multiple batches of the enzyme as well
as the activity of similar enzymes on the same substrate. In
addition, these values are a necessity in the development of a
compound screening assay because they directly relate to the
modes of inhibition that can be detected with a given
concentration of substrate (Copeland, 2003). Methodology and
application of Michaelis–Menten kinetic parameters will not be
discussed herein; however Copeland presents a thorough review
of these concepts as applied to drug discovery (Copeland,
2005). Instead, we will address in detail those assay parameters
that should be evaluated in the transition from an active
enzyme preparation to a HTS-compatible assay.
Figure 2 Michaelis–Menten kinetics applied to HTS. (A) Determina
accomplished by following the time-course of reaction at multiple
velocity can be measured and this is plotted against the substrate co
(VmaxKm) / ([Substrate] + Km), where Vmax = kcat [Enzyme]. (B
based compound screen. Applying the Michaelis–Menten constant an
control samples (open squares) and activity control samples (closed
et al. (1999)) of the assay. The closed circles represent each com
inhibition, with a small fraction of inhibitory compounds falling off
Figure 1 Strategies to develop enzyme assays. Top, enzyme
assays can be developed to measure the free enzyme, substrate
depletion, or product formation. Bottom, example methods
employed in enzyme assays. Displacement-binding methods have
been used to measure compounds binding to enzyme using either
labeled substrates (A, i) or a labeled inhibitor (A, ii). Enzyme
activity has been monitored through measuring the remaining
substrate in which the signal that is generated is directly propor-
tional to the amount substrate present (B). Product formation can
be measured using a labeled substrate that is converted to a
ﬂuorescent product (C, i), through use of coupling enzymes which
can be the same coupling enzymes (C, ii), and antibodies can be
used to measure speciﬁc products in a displacement binding mode
where a labeled product is initially bound to an antibody (C, iii).
M.G. Acker, D.S. Auld58Enzyme
At the heart of an in vitro biochemical enzyme assay for
drug discovery is the form of the enzyme to be targeted.
In the cellular context, the enzyme most likely acts in
combination with other enzymes and proteins, as either a
single entity in a larger signaling or metabolic cascade, or
more commonly as a member of multimeric complexes that
are required to direct the temporal and positional activity
of the target. In cells, enzymes often exist in multiple forms
arising from the same (splice variants) or different loci in
the genome. In contrast, in a reconstituted biochemical
system, the enzyme is often isolated, lacking many or all of
its native binding partners, which can signiﬁcantly affect
enzyme stability and activity in vitro. Additionally, it may
be difﬁcult to express and purify the enzyme in its native
form due to size and/or stability limitations in the absence
of these partner proteins. Hence, numerous constructs are
often attempted in the expression and puriﬁcation of the
desired enzyme, including truncated variants and alterna-
tively tagged species in an attempt to maximize protein
yield, stability and activity. A caveat of these artiﬁcial
alterations is that the more one diverges from the natural
protein, the more likely it is to identify compounds that lack
a physiologically relevant mechanism and to miss com-
pounds that work under physiological conditions.
The choice of which protein construct to employ for
development of the enzyme assay depends on several
factors. Initial tests that assess differences in both the
activity and stability of protein constructs are critical in
deciding which constructs to advance. In addition, the use
of “tool” compounds, that is compounds with known modes
of inhibition (MoI), can be extremely revealing in evaluating
which construct to ultimately use in a HTS based on the
desired MoI. When multiple constructs of an enzyme use the
same substrate, it is possible to compare their activities
using the Michaelis–Menten constants in the form of kcat/Km.
This takes into account both the rate determining step
which limits the maximal velocity of the enzyme reaction
(expressed in the constant kcat) and the propensity of the
substrate to be turned over to product (Km). While subtle
differences in the rate and or Km may exist amongtion of the Km and kcat for a reaction with a given substrate is
concentrations of substrate. For each time-course, the initial
ncentration and ﬁt to the Michaelis–Menten equation velocity =
) A plot of single-concentration inhibition values from a plate-
d setting [Substrate] E Km, the screen is run including neutral
squares) which are used to calculate the robustness (Z0, Zhang
pound that was screened. Note that most compounds show no
of the horizontal.
59Enzyme assays in high-throughput screening applicationsconstructs, large differences in kcat/Km can indicate sig-
niﬁcant differences in the structure and/or stability of the
construct. Additionally, the speciﬁc activity can also be used
to compare different preparations of the same enzyme
construct. The speciﬁc activity is the Vmax (calculated at
saturating amounts of substrate) divided by the mass of
enzyme in the reaction and is usually expressed in μmol
min1 mg1. A severe decrease in assay performance may
be indicative of poor batch reproducibility or indicate a
decay in batch activity which can be checked by monitoring
the speciﬁc activity between different enzyme batches or
different samples of enzymes from the same batch.
The purity of the enzyme target must also be considered,
as the use of an impure enzyme preparation can lead to the
selection of aberrant or mis-targeted inhibitor compounds.
Enzyme purity can be assessed in a number of ways. The
enzyme sample can be analyzed via mass spectrometry,
yielding not only the identity through comparison with the
expected mass, but also the relative purity based on the
ratio of the desired mass peak to other mass peaks in
the sample. The enzymatic purity (that is, the fractional
activity contributed by the desired enzyme) is more difﬁcult
to analyze and requires analysis of the IC50 curves of known
inhibitors, or in the absence of such inhibitors, determina-
tion of the Michaelis–Menten parameters and comparison
with published or previous results (Scott et al., 2004).
Variations in purity can be minimized by using selective
substrates with low Km values and low (nM) concentrations
of enzyme.
When setting up an assay for compound screening, one
must be aware of the effects of compound vehicle on the
activity of the enzyme. Signiﬁcant numbers of compounds in
commercial and other compound libraries are poorly soluble
in water and therefore the compounds are stored in an
alternate solvent (dimethylsulfoxide (DMSO), dimethylfor-
mamide (DMF), methanol, etc.). As these vehicles are
themselves low molecular weight molecules, they could
impair enzyme function at relatively low concentrations.
Vehicle sensitivity can be evaluated by titrating the vehicle
over a relevant range of concentrations and monitoring any
change in activity of the enzyme. In general, the acceptable
level of inhibition due to vehicle concentration will dictate
the top compound concentration which can be screened.
Additionally, enzymes can interact poorly with tubing and
surfaces required for dispensing liquids into assay plates
during HTS. In particular, enzymes can often bind irrever-
sibly to tubing, resulting in a decrease in the effective
enzyme concentration until the tubing becomes blocked
with enzyme. This can be thwarted by including BSA or small
amounts of detergent (for example TWEEN, Triton, Brij-35,
or CHAPS at concentrations o0.1% have been used) in the
assay buffer, however such additives can also affect com-
pound interactions with the enzyme either by sequestering
the compound or effecting enzyme activity. It is imperative
that these tests be performed early to identify and solve
stability issues before moving to compound testing.Substrate
Like the enzyme construct, the substrate form chosen for
compound screening assays can play a signiﬁcant role in theinhibitors identiﬁed. Peptide mimic substrates will occupy a
smaller region on the enzyme than the full-length substrate
protein, perhaps eliminating the opportunity to identify
non-active site inhibitors. However, native protein sub-
strates may not be conducive to HTS due to poor expres-
sion/solubility or perhaps the native substrate is unknown.
Similar to the enzyme target, the caveats of choosing one
form of substrate over another should be considered before
advancing into full assay development.
Whichever form of substrate is chosen, the concentration
of the substrate(s) relative to their Km values will have the
biggest impact on the type of inhibitors that will be
identiﬁed. Whether competitive, non-competitive, uncom-
petitive compounds or mixed inhibitors are identiﬁed
depends on the concentration of the substrate chosen
relative to the Km for that substrate. Competitive inhibitors
bind orthosterically to the active site where the substrate
usually occupies the enzyme, therefore competing with the
substrate's ability to bind. In general, as the concentration
of substrate in the assay increases above Km, there is a
higher probability of the substrate occupying the active site
over the inhibitor at a ﬁxed concentration of the inhibitor.
Therefore, increasing the concentration of substrate
decreases the ability of competitive inhibitors to bind and
inhibit an enzyme. Uncompetitive inhibitors (a mechanism
that is often observed in two-substrate enzyme assays using
an ordered binding mechanism) bind to the enzyme only
when the enzyme has already bound a substrate molecule.
At concentrations below the substrate Km, very little
enzyme-substrate complex exists and therefore there is a
low probability of uncompetitive compounds inhibiting the
enzyme. In searching for uncompetitive inhibitors, the ﬁrst
substrate is usually present at high concentrations to drive
its binding and enhance the binding of uncompetitive
inhibitors. Non-competitive compounds bind the enzyme
at an allosteric site, independently of the substrate mole-
cule. Because of this, binding of the inhibitor is unaffected
by substrate binding and therefore is unaffected by sub-
strate concentration. From these explanations, it becomes
clear that the choice of substrate concentration relative to
Km can skew the inhibitor proportions immensely. In gen-
eral, running an enzyme assay with substrate concentration
at the Km is optimal to identify inhibitors of all three classes
(Yang et al., 2009) (Figure 3). High substrate concentration
will enrich for uncompetitive compounds, while low sub-
strate concentrations will enrich the competitive inhibitors.
Note that at all concentrations of substrate one should be
able to identify non-competitive inhibitors (Copeland, 2003;
Yang et al., 2009). It should be noted that direct comparison
of IC50 values between compounds exhibiting different MoI
is irrelevant due to the fundamental kinetic parameters
driving the various inhibition modes. Only the Ki can be used
to compare in a meaningful way the level of inhibition
between compounds of different inhibition modes. Ki and
IC50 are related through a series of equations, described by
Cheng and Prusoff (1973), but this comparison requires
knowledge of the respective MoI for the compounds of
interest (Cheng and Prusoff, 1973).
In addition to its effect on inhibitor modality, substrate
concentration also directly correlates with the signal inten-
sity of the assay. Increasing the concentration of substrate
should increase the turnover of the assay until the substrate
Figure 4 The %conversion can affect the assay sensitivity.
Shown are example data for two reversible inhibitors (solid
lines, IC50 = 100 nM; dotted lines, IC50 = 10 μM) and the
theoretical IC50 curves at different % conversions. 10%, red; 40%,
blue; 60%, green; 80%, orange; 90%, black and 98%, purple).
Shifts in IC50’s were calculated as described in Wu et al. (2003).
Figure 3 Effect of [S]/Km on inhibitor sensitivity. The ratio of
substrate concentration to Km ([S]/Km) inﬂuences the ability to
identify compounds of different modes of inhibition. Using the
Cheng–Prusoff equations for compounds with competitive, non-
competitive or uncompetitive modes of inhibition (Ki=1 for all
three), these curves represent the theoretical response of IC50
values at varying [S]/Km ratios. The responses for uncompeti-
tive and competitive compounds are mirror images or each
other, showing maximal sensitivity at high and low [S]/Km
ratios, respectively, while the IC50 of non-competitive com-
pounds does not change with regard to [S]/Km. This graph
clearly depicts [S]/Km = 1 as the optimum ratio for identifying
inhibitors for any of the three modes of inhibition. Compounds
of all three modes of inhibition display relatively low IC50 values
at this ratio, which corresponds to an assay where the
concentration of substrate is equal to the Km for that substrate.
Source: (adapted from Copeland (2003)).
M.G. Acker, D.S. Auld60is saturating the enzyme. This saturation point often provides
the largest signal-to-background ratio that can be obtained
for an assay, but as discussed above, may not provide the
correct environment for identifying inhibitors of the desired
modality. Therefore, there must always be a balance
between signal window (Iversen et al., 2006) and desired
inhibitor modality when choosing a substrate concentration.
As well, one has to be careful to ensure that the amount of
substrate turned-over is kept low when optimizing the signal
window of the assay to ensure the identiﬁcation of weak
inhibitors (Inglese et al., 2007) (Figure 4). It is important to
keep in mind that while running the assay at high conversions
(480%) may greatly improve the signal window, such high
levels of conversion will lead to weaker IC50s (Wu et al.,
2003). Finally, substrate concentrations can be limited by the
ability of the substrate to dissolve in the assay buffer, limiting
the top concentration possible, and the types of inhibitors
that can be identiﬁed. Solubility limitations should manifest
themselves as a poorly ﬁt Michaelis–Menten curve, which
result in an uncharacteristic plateau of the rate and can also
result in a drop in enzyme activity at high concentrations due
to substrate aggregates which decrease the concentration of
substrate below the solubility limit.
The physical properties of substrate molecules should be
considered when adapting a biochemical assay to HTS. Because
of the large number of compounds that need to be screened,
automation using robotic systems is often employed. Auto-
mated protocols can involve leaving reagents for extendedperiods of time under conditions where the substrate is sup-
optimal for stability, ultimately leading to degradation of the
substrate over time. In addition, substrate molecules could
interact poorly with the tubing and surfaces involved in the
automation of dispensing assay plates for HTS. Stability tests
should be performed early on in the assay optimization process
to identify stability effects which might occur on the HTS
system and modiﬁcations made to address any issues that are
identiﬁed.Cofactors
Many enzymes require cofactors for structural integrity or that
assist in the reaction of substrate to product. A cofactor can
remain unchanged during the reaction, or may cycle through
various states during the reaction cycle. However, by deﬁnition
the cofactor is not consumed in the reaction, and instead
returns to its original state, able to participate in the reaction
over and over again. Cofactors can be tightly bound, never
truly dissociating from an enzyme or they can be transient,
binding and dissociating in equilibrium. Common cofactors
include metals (a zinc ion bound at the active site; coordinat-
ing magnesium; iron which exists in various redox states for
catalysis) and organic compounds (FAD/FADH2 involved in
hydride transfer; PLP in transamination reactions). Depending
on the afﬁnity of the enzyme for a particular cofactor, the
enzyme may be puriﬁed with the cofactor or additional
cofactor may need to be added to the assay to maximize
enzymatic activity. The afﬁnity of the cofactor will also
61Enzyme assays in high-throughput screening applicationsinﬂuence whether a compound that competes with cofactor
binding can be identiﬁed.
The effects that exogenous cofactor have on bioche-
mical enzyme assays can often be treated like substrate
addition – the amount required depends on the level of
activity needed and the necessity of the cofactor for the
enzyme form one chooses to inhibit. In general, if additional
cofactor is required to obtain a robust enzyme assay, then it
is usually best to use a saturating concentration in the assay
when not speciﬁcally screening for cofactor-competitive
compounds. Titrations of the cofactor should also be
performed to identify the best possible signal:background
ratio and to ensure that the reaction is not inhibited at high
concentrations of cofactor. Cofactors can also interfere with
product detection depending on the method used and
therefore the necessity for cofactors may ultimately dictate
which detection technique can be applied to a particular
target. Finally, stability of a cofactor needs to be consid-
ered for the time and environment that the cofactor will be
exposed to during an HTS run. For example, some cofactors
are light sensitive (iron guanylyl pyridinol) while others can
change redox state in common buffers without reducing
agents (iron salts). The timing of these modiﬁcations must
be considered and tested to assure compatibility with the
HTS process.Buffers
Typically, in vitro biochemical assays are performed at near
physiological pH in an attempt to mimic the intracellular
environment of the native enzyme. Most enzymes will show
broad pH sensitivity due to denaturation at high/low pH or to
protonation/deprotonation of residues directly involved in
acid-base chemistry. For cytosolic proteins, pHE7.4 can be
maintained by a number of buffers including Tris, HEPES,
MOPS, and sodium or potassium phosphate buffers, to name a
few. However simply because an enzyme is found in the
cytosol does not guarantee that the activity will be optimal at
pH=7.4. A range of pH values encompassing pH=7.4 should be
tested in enzymatic activity assays, taking into account that
differences in the local environment in vitro versus in vivo or
changes in the protein construct from the native form could
alter the optimum pH for reactivity. However diverging too far
from physiological pH in a biochemical assay can alter the
interaction between the enzyme and compounds, creating a
potential disconnect between the biochemical and cellular
activity of these compounds.
The choice of buffer can also have signiﬁcant consequences
for a biochemical reaction because each buffer can have
unique and signiﬁcant effects on a given enzyme target. In
addition, necessary reaction components can interact poorly
with certain buffers, resulting in non-optimal assay conditions
and affecting the robustness and reproducibility of an assay.
For instance, phosphate buffer is incompatible with reactions
requiring Mg2+ or Ca2+ cofactors because the phosphate salts
of these metals are poorly soluble in aqueous buffer, therefore
depleting a needed component of the reaction. Such pre-
cipitates can also affect the HTS resulting in poor liquid
dispenses on the automation equipment. Tris buffer contains
a free amine group which can react with enzymes and/or
substrates, altering the equilibrium of the system. Tris is alsoable to chelate metal ions which could have deleterious
effects on the activity of enzymes requiring metals for
catalysis or structure (Desmarais et al., 2002).Detection methods
There are many subtleties to consider when choosing a
detection method for following an enzymatic reaction
in HTS, including throughput, sensitivity, cost and assay
robustness, as well as the nature of the reaction under
investigation and that of the products and/or substrates to
be measured. No detection method is perfect – they are all
utilized with some caveats – but for most enzyme classes, it is
possible to strike a balance between these requirements to
develop a useful assay. Many of the methods that are
introduced here will be discussed with respect to speciﬁc
enzyme classes and technologies later in this review.Continuous versus quenched reactions
Directly monitoring a reaction as it is happening is referred
to as a continuous read. Continuous reading typically
requires a spectrophotometer/ﬂuorometer capable of
rapidly collecting data from multiple time points and the
ability of the molecules being monitored to absorb or emit
light in a reaction dependent way. Some examples of
suitable systems used in continuous detection are observing
the change in either absorbance or ﬂuorescence upon the
interconversion of NAD and NADH, the production of ﬂuor-
escent labels such as amino methyl coumarin (AMC) by
proteolysis of AMC-labeled peptides, and the ability to
observe changes in light scattering upon large protein
complex formation. Continuous detection provides the
advantage of observing an entire reaction time course from
a single mixture of substrate and enzyme, which minimizes
the error in data by minimizing the need for multiple
transfers and excess handling of the reaction components.
However timing is a key variable that must be controlled
particularly if a single time point is chosen for the assay as it
can be difﬁcult to stop a continuous reaction without
disrupting the system or interfering with detection.
In the speciﬁc case of ﬂuorescence detection for enzyme
assays one method to address “overriding” of the assay
signal by compound ﬂuorescence is to measure the reaction
progress in a kinetic mode. Unless the reaction under study
is slow, on the order of tens of minutes, only fast-scanning
readers or whole-plate imagers (such as the PerkinElmer
ViewLux™) allow for unbiased and speedy repeated mea-
surements of microtiter plates. However, often a simple
method where two-time points are collected allows one to
estimate the reaction rate by simple subtraction of the two
data points. In this manner, the effects of dust and
ﬂuorescent compounds are subtracted out to reveal the
true reaction course. An added beneﬁt from kinetic reading
is that the signal-to-background computed from kinetic
measurements can be over 100 fold enabling screening
under conditions of low substrate conversion.
In contrast, a quenched reaction occurs by running many
small scale reactions and stopping these at various times by
adding a reagent that inhibits the enzyme without destroying
the product that has been formed. Quenched reactions are
carried out when it is not possible to detect changes in the
system (e.g., product formation) during the course of the
Figure 5 The hook effect. The hook effect results from
saturation of two-component indirect detection reagents with
product. In a typical two-component detection system, each
component must co-ordinate with a single product molecule in
M.G. Acker, D.S. Auld62reaction without interfering with the reaction. For instance,
many products such as inorganic phosphate or metabolic
intermediates cannot be visualized via spectrophotometric
methods in a continuous mode. Therefore, the reaction must
be stopped and the products observed by another method,
either by indirect detection using a reagent or a coupling
enzyme (see below) or using analytical techniques such as
radiography or mass spectrometry. Quenched reactions lend
themselves to high throughput methods because many reac-
tions can be run simultaneously and stopped, allowing detec-
tion to at a speciﬁc reaction time, typically chosen based on
kinetic data and the percent conversion of product. However,
collecting kinetic data by performing multiple quenched reac-
tions typically leads to more variable data than continuous
modes of detection because of the increased reagent transfer
steps inherent to quenched reactions leading to more variation
between samples. In addition, the time points taken are
limited by the liquid handling capabilities and the physical
constraints that dictate the time of detection between two
quenched reactions.order for the signal (photon, singlet oxygen, etc.) to be
generated. As product reaches a concentration at which the
detection reagents are consumed and can no longer respond in
a dynamic manner to increasing product, the reaction curve
plateaus. Further increase in product concentration results in a
decrease in signal as the two components required for detec-
tion become so dilute that the probability of these occupying a
single product molecule drops to zero. In the example shown a
TR-FRET assay is depicted where a europium-labeled antibody
binds to a phosphorylated peptide (represented by the green
oval on the blue strand) which is biotinylated (orange square)
allowing binding to streptavidin labeled with allophycocyanin
(XL665).Direct versus indirect detection
Often, the product of a reaction is difﬁcult to detect directly
either due to properties such as size, stability or solubility of
the molecule, or because the product is spectroscopically
silent using current direct detection technologies. In this
case, a coupled or indirect measurement is needed to follow
the progress of a reaction. Consider a typical GTPase enzyme
involved in cell signaling. The substrate (GTP) and products
(GDP and Pi) are quite small, making them difﬁcult to
separate/quantitate via liquid chromatography mass spec-
trometry (LC/MS). Additionally, neither molecule is condu-
cive to spectrophotometric detection techniques, and short
of using radioactive isotopes, direct detection of products is
nontrivial. Therefore, an indirect detection system is useful.
In this case, a ﬂuorescently labeled phosphate binding
protein (PBP) binds to Pi with an extremely high afﬁnity,
which results in an increase in ﬂuorescence of the protein.
The signal observed is due to PBP binding to Pi, not from Pi
itself, but by coupling the PBP within the reaction (Lavery
et al., 2001). Another method to detect Pi product formation
in an indirect manner uses malachite green and the inherent
ﬂuorescence of white microtiter plates (Zuck et al., 2005).
Indirect detection of products requires a thorough under-
standing of the entire system at work. The indirect detection
methods must be sensitive enough that even small amounts
of product can trigger a signal from the coupled system. In
other words, the secondary detection system cannot be
rate-limiting or the kinetics of detection will be observed,
not the kinetics of the reaction. Alternatively, the detection
reagents must be in sufﬁcient quantity to detect generated
product amounts without being consumed completely. For
instance, in two-component detection systems such as HTRF,
high amounts of product can saturate the detection compo-
nents, leading to an artiﬁcial plateau in the reaction curve.
This can be mistakenly interpreted as having reached
equilibrium, when in fact, allowing the reaction to continue
will actually generate a decreasing curve. This “hook effect”
is common and can be observed, for example, when titrating
a biotinylated peptide which is recognized by an antibody-
linked to a donor ﬂuorophore to create a FRET signal whenan appropriate acceptor ﬂuorophore is in close proximity
(Figure 5). The “hook effect” can be identiﬁed by generating
a product standard curve and testing various concentrations
of detection components. Finally, the interference by the
compounds being assayed with the coupled system must be
considered.
With the many caveats of indirect detection systems,
there are still many situations in which an indirect detection
method is superior to a direct detection method. Particu-
larly for use in HTS, many direct detection techniques
(radioactive substrates/products, Western blots, HPLC,
NMR) cannot be adapted for the throughput and automation
required to efﬁciently process large numbers of compounds.
The cost of reagents and supplies must also be weighed
when considering a detection technique and the cheapest
option in the short term may be the least cost effective over
the course of an entire screen. Many of the enzyme assays
used in HTS that are discussed in the next section involve
indirect detection methods.
As an example of direct detection, mass spectrometry is
often an ideal method for assays involving post-translational
modiﬁcations such as hydroxylation, phosphorylation or acet-
ylation of substrate peptides, limitations on maximum
throughput capabilities may preclude the use of this techni-
que in favor of an indirect detection method such as time-
resolved-ﬂuorescence energy transfer (TR-FRET) or Ampliﬁed
Luminescent Proximity Homogenous Assay (AlphaScreen™,
see below). For instance, a multiplexed LC/MS detection
63Enzyme assays in high-throughput screening applicationsprotocol can process samples at 30 s per well, or about 3 h per
384w plate. At 8 plates per day, it would take 47 non-stop
weeks to screen a deck of 1 million compounds, not counting
controls. However using HTRF detection and a ViewLux which
can read a 1536-well plate in approximately 2 min, the same
screen can be accomplished in 22 h of total read time, saving
both time and money. Some speciﬁc examples are given in the
next section.Figure 6 Bioluminescent orthogonal assays for ATP consuming
enzymes. Shown is the raw luminescence counts obtained by
measuring either ATP depletion (KinaseGlo, solid circles) or ADP
formation (ADPGlo, open circles) upon inhibition of the Clk4
kinase by an LMW inhibitor (CID:3232621).
Source: Adopted from Tanega et al. (2009).Assays for HTS of enzymes
Protein kinases
Protein kinases (EC 2.7.10/EC 2.7.11) which phosphorylate the
hydroxyl group present on serine, threonine, or tyrosine
residues represent an enzyme family for which many assays
have been developed due to their central role in controlling
signaling pathways (Glickman et al., 2004). Measurement of
substrate depletion by detecting the remaining ATP in a kinase
assay using ﬁreﬂy luciferase (EC 1.13.12.7) is an example of a
generic assay format for protein kinases (Koresawa and Okabe,
2004; Singh et al., 2004). The use of a bioluminescent signal
for ATP levels results in an increase in luminescence when the
kinase is inhibited. Drawbacks of the ATP depletion method
include the need to run the assay at high substrate turnover
which often requires larger amounts of enzyme, the assay is
performed using single endpoint, and the assay requires the
presence of a luciferase coupling enzyme. This latter point
requires that appropriate counter-screens against luciferase
alone are performed (Auld et al., 2008). Additionally, as the
system measures substrate depletion, the standard steady-
state assumption that SoSt does not apply, thus confounding
MoI studies. The assay is best performed using 50% conversion
of substrate where the signal:background ratio is 2-fold, a
range often yielding acceptable assay performance for lumi-
nescent assays, and the expected shift in IC50 from ideal initial
rate conditions is expected to be o2-fold (Wu et al., 2003).
A more desirable method to measure enzyme activity is
by detecting product formation. Recently, generic methods
for kinase assays have been developed that detect the ADP
product. These include both a non-antibody based system
that employs coupling enzymes with a ﬂuorescent readout
(DiscoveRx, ADP Quest™; λex=530 nm, λem=590 nm)
(Charter et al., 2006) and a system that uses an ADP
speciﬁc antibody and red-shifted FP by employing an
Alexas 633-labeled ADP (BellBrooks Lab, Transcreener™;
λex=612 nm, λem=670 nm) (Huss et al., 2007; Kleman-
Leyer et al., 2009). The red-shifted ﬂuorescence limits
ﬂuorescent interference by compounds and the ratiometric
nature of FP aides in minimizing artifacts due to liquid
handling. The BellBrook system has also been adapted to a
TR-FRET format employing terbium labeled ADP-antibody
and ﬂuorescein labeled ADP (Klink et al., 2008). The TR-
FRET format of this assay limits interference by faster
decaying background ﬂuorescence due to compounds or
buffer components (Comley, 2006). Indeed, with any
ﬂuorescent-based assay, a consideration of interference
by ﬂuorescent compounds (Simeonov et al., 2008) or by the
inner-ﬁlter effect (Palmier and Van Doren, 2007) needs to
be considered. Low-molecular weight (LMW) compounds
present in typical chemical libraries can show a good-dealof blue ﬂuorescent, therefore using red-shifted ﬂuoro-
phores for detection can reduce interference by compound
ﬂuorescence (Simeonov et al., 2008).
One draw-back for the antibody-based assay system is
that variation of ATP for enzyme kinetic studies is compli-
cated by a required calibration of the antibody concentra-
tion based on the ATP/ADP ratio. In contrast, the coupled
enzyme system from DiscoveRx has been shown to be useful
for determining the MoI using a kinetic mode of detection
(Charter et al., 2006). With this in mind, the coupled
enzyme system is more attractive for MoI studies. However,
the DiscoveRx system uses three coupling enzymes to
generate the signal so care must be taken to ensure that
the inhibition is target speciﬁc, although these enzymes are
present in excess amounts.
A bioluminescent assay for ADP has also been developed for
protein kinases (Larson et al., 2009; Sanghera et al., 2009;
Vidugiriene et al., 2009). Following the kinase reaction, the
remaining ATP is depleted using a soluble adenylate cyclase
and the ADP product is then converted back to ATP with
pyruvate kinase, ﬁnally bioluminescent detection of ATP is
achieved with ﬁreﬂy luciferase by adding the substrate, D-
luciferin. The assay, known as “ADP-Glo” (Promega) provides
an orthogonal assay to the bioluminescent substrate depletion
assay mentioned above. Genuine inhibitors will show a
opposite luminescent responses in the two assay formats
which will ﬂag direct inhibitors of the coupling enzymes
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be very useful for detecting assay format/reporter-speciﬁc
activity which can oftentimes complicate the interpretation of
results from HTS assays (Thorne et al., 2010). A general
consideration when employing either ATP or ADP detection
for kinases is that the preparation must be free of any
contaminating ATPase activity and some kinases may contain
intrinsic ATPase activity. In these cases measurement of
phosphorylated peptide product is required. Both the ATP
depletion method mentioned above and the ADP formation
assay systems allow incorporation of physiological polypeptide
substrates into the assay.
Assay systems for protein kinases that detect the phos-
phorylated peptide product include both antibody and non-
antibody dependent systems. Newer antibody-dependent
systems include the use of universal biotinylated peptides
and monoclonal antibodies labeled with a europium cryp-
tate to construct HTRF assays for either serine/threonine
kinases or tyrosine kinases (HTRFsKinEASE™, Cisbio). Non-
antibody dependent systems represent generic methods to
detect the presence of phosphorylated peptide/protein
products analogous to the ADP detection systems mentioned
above. These include the use of metal chelated particles
such as in Molecular Device's Immobilized Metal Ion Afﬁnity
Particles (IMAP) technology (Beasley et al., 2004; Gaudet
et al., 2003; Loomans et al., 2003; Sportsman et al., 2004;
Turek-Etienne et al., 2003). The use of metal ions to bind
functional groups such as phosphate is well documented in
the literature and is based on Pearson's HSAB theory
(Pearson, 1966). Metal ions such as GaIII, AllII, FeIII are
known to bind phosphate in an nonionic manner (Porath
et al., 1975). In the case of IMAP, the ﬂuorescently labeled
peptide forms a complex with metal-chelated nanoparticles
that is easily measured using FP. As well, iron chelates have
been employed to bind phosphorylated peptides labeled
with ﬂuorescein which results in quenching of the ﬂuor-
escein ﬂuorescence (“Iron Quench”, or IQ technology)
(Morgan et al., 2004). The limitation of FP based-
detection is that the polypeptide product must be
o10,000 MW when ﬂuorescent labels with typical lifetimes
are used, which will prevent the use of full length physio-
logical substrates. However, IMAP has been adapted to FRET
based systems where size limitations on the polypeptide
substrate are less restrictive, although the distance
between the donor and acceptor ﬂuorophores must be
within 10 nm for Förster resonance energy transfer to occur
(Klumpp et al., 2006).
A convenient alternative to IMAP that has been applied to
both kinases and phosphatases is to use polyarginine instead of
IMAP beads. Nikiforov and Simeonov (2003) explored assays
based on the change of two charge units in a peptide upon
addition/removal of a phosphate group. In the assay, the
negative charge shift results in a change in peptide afﬁnity
towards an oppositely-charged arginine homopolymer. With
proper adjustment of the ionic strength and optimization of
assay conditions even systems such as that of LAR phospha-
tase, where the substrate Fl-DADE(pY)L-CONH2 carries a net
charge of 7 while its dephosphorylation product is 5
charged, can be monitored by this approach.
A hybrid system that employs both a coupling enzyme and
sometimes an antibody is represented by enzyme fragment
complementation (EFC; HitHunter™, DiscoveRx) technology.In one example, β-galactosidase is split to create a so-called
enzyme acceptor (EA) fragment and an enzyme donor (ED)
peptide (approximately 4 kDa) (Eglen, 2002; Eglen and Singh,
2003). To construct a kinase assay, the ED peptide is
synthesized to contain a phosphorlyated peptide sequence
so that a competitive immunoassay is set up using antibodies
that are highly speciﬁc for the phosphorylated peptide.
Production of unlabeled phosphorylated peptide by the
kinase frees the ED-labeled phosphorylated peptide from
the antibody allowing reconstruction of active β-
galactosidase which is then detected.
Another technique without the size limitations of FP that
has been applied to kinases is AlphaScreen (Burns et al.,
2006). AlphaScreen employs 250 nm diameter beads con-
taining chemiluminescent reagents to create donor and
acceptor beads (Ullman et al., 1994). Irradiating the donor
bead with a high intensity laser emitting light at 680 nm
excites a photosensitizer in the beads which results in
conversion of ambient oxygen to singlet oxygen. A large
amount of singlet oxygen is produced (60,000 molecules/s)
resulting in large signal ampliﬁcation. If an acceptor bead is
within 200 nm the singlet oxygen will result in exciting
ﬂuorophores in the acceptor bead which emits at a shorter
wavelength. Two different acceptor beads can be used: with
AlphaScreen acceptor beads, ﬁnal emission is from rubrene
(λem=520–620 nm); with AlphaLISA acceptor beads, the ﬁnal
emission is from europium that is doped into the beads
which shows a much narrower emission spectrum (λem=615
nm). For protein kinases, typically a biotinylated peptide
substrate is conjugated to streptavidin coated donor beads
and a phosphospeciﬁc antibody is conjugated to protein A
coated acceptor bead (Von Leoprechting et al., 2004).
Because long wavelength light is used for excitation and
emission occurs at shorter wavelengths, optical interfer-
ence of the excitation light by compounds is reduced.
However, AlphaScreen has been shown to be susceptible
to compound interference by color quenchers of the emis-
sion light as well as anti-oxidants, singlet oxygen quenchers,
and biotin mimetics if streptavidin coated beads are used
(Baell and Holloway, 2010). Another consideration in devel-
oping AlphaScreen assays is that variation of the biotiny-
lated peptide substrate will show a “hook-effect” (as
mentioned above) at high substrate concentrations due to
saturation of the streptavidin donor bead binding sites – the
signal ﬁrst increases with increasing peptide, then levels off
and starts to decrease when excess peptide is used as the
proportion of productive donor acceptor bead complexes
decreases due to the excess peptide in the assay (Quinn
et al., 2010).
Therefore, it is not possible to determine Km values for
the peptide substrate using AlphaScreen as binding capacity
of the beads limits the detectable range of substrate
concentration. An advantage of this detection strategy is
that the large distance dependence (200 nm) allows the
employment of physiologically relevant substrates.
Analytical approaches to kinase detection include micro-
ﬂuidic systems for separation based on electrophoretic and
electro-osmotic properties of the labeled species (Cohen
et al., 1999). In one such technology platform (Caliper,
PerkinElmer), optimization of the elution gradient on the
UPLC system allows one to run kinase assays at extremely
low substrate conversion rates (Wu et al., 2006). In this
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product is provided and detection and interfering ﬂuores-
cent compounds are readily ﬂagged.
With generic systems available that detect ATP/ADP
conversion one could ask if there is any advantage to
protein kinase assay systems that rely on detection of
phosphorylated peptides, especially when peptide-based
systems are oftentimes incapable of incorporating natural
protein substrates. However, in some instances the kinase
will phosphorylate more than one site on the substrate used
in the assay and if the goal is to prevent phosphorylation at
a speciﬁc site it will be an advantage to employ antibody-
based systems (Kristjansdottir and Rudolph, 2003). As men-
tioned above, some ATP/ADP detection systems report an
indirect measurement of kinase activity through the use of
coupled enzyme systems and appropriate counter-screens
for the coupling enzymes need to be performed. Further,
such generic systems involving ATP or ADP detection cannot
provide multiplexed readouts of kinase activity and intrinsic
or contaminating ATPase activity may interfere with detec-
tion of peptide-speciﬁc phosphorylation.
The use of radiolabeled ATP (either 32P or 33P placed at
the γ-position of ATP) to measure phosphorylation of poly-
peptides is one of the earliest assays used to measure kinase
activity in HTS. This approach historically employed a ﬁlter-
binding assay to separate radiolabeled protein/peptide
products from free radiolabel. Due to the required wash
and separation steps the ﬁlter-binding format is low-
throughput. However, this assay format still represents the
gold standard for kinase assays and is often the method of
choice for determining kinase selectivity or MoI studies.
Higher throughput radiolabeled kinase assays that cap-
ture and count phosphorylated products in a non-
separation-based format employ a scintillation proximity
assay (SPA) format or FlashPlates (Glickman et al., 2008). In
SPA a speciﬁc signal arises when a radiolabeled substrate is
bound to a bead containing a scintillation matrix. For
example, a biotinylated peptide is phosphorylated by a
kinase in the presence of radiolabeled ATP and streptavidin
coated SPA beads are added to the wells of microtiter plates
to detect the phosphorylated peptide product. However,
one drawback of this approach, which is true of all non-
separation based assays, is that the compounds being tested
remain in the well during detection and some compounds
can interfere with the emission light that is detected. In
SPA, quenching by yellow and red colored compounds can be
observed (Glickman et al., 2008). Other versions of SPA are
available where the beads are doped with red-shifted
ﬂuorophores providing emission of red-shifted light which
will limit compound absorption by LMW compounds present
in typical chemical libraries. Red-shifted SPA and Flash-
Plates yield emission at 615 nm and can be detected rapidly
using a CCD (charge-coupled device) imaging-based micro-
plate reader (e.g. PerkinElmer Viewlux™). However,
despite the high sensitivity of radiometric assays, disposal
of radioactive waste and safety considerations has made
this approach increasingly unpopular, especially given the
wide range of non-radioactive formats now available.
Proteases have also been used to construct kinase assays.
In FRET-based protease assays, cleavage of the peptide by
the protease results in loss of FRET. However, when these
FRET-labeled peptides are engineered to contain a kinaserecognition site one can construct assays where the pro-
tease recognition sequences are blocked by phosphorlyla-
tion at residues residing near the scissile bond cleaved by
the protease. In this way a protease mediated FRET read-
out (Z-lite™, Invitrogen) can be used as an assay for kinase
activity (Rodems et al., 2002).
Protein kinase assays can be set up a variety of ways
depending on the desired mode of action. For example,
screening the inactive state of a protein kinase to ﬁnd type
II inhibitors can be achieved by incorporating a kinase
activation step within the assay system or activity indepen-
dent systems such as binding methods (Lu et al., 2004;
Newbatt et al., 2006; Vainshtein et al., 2002). Competition-
binding assays have been developed using ATP competitive
compounds which have been applied to proﬁle selectivity of
inhibitors against 442 members (80%) of the human kinome
(Davis et al., 2011). Modern protein kinase assays attempt
to use technologies where the native substrate can be
incorporated into the assay to improve the physiological
relevance of the assay.
Phosphatases
Both protein tyrosine (EC 3.1.3.48) and serine (EC 3.1.3.3)
phosphatases are of interest for drug discovery. The ﬂuoro-
genic tyrosine phosphatase substrate diﬂuoromethyl umbel-
liferyl phosphate (DiFMUP) is one of the most commonly
employed substrates for tyrosine phosphatase assays (Gee
et al., 1999). Fluorogenic substrates based on ﬂuorinated
umbelliferones remains the substrate of choice for contin-
uous assays of phosphatases. Enzyme-catalyzed hydrolysis of
the phosphate group liberates the blue-ﬂuorescent diﬂuor-
omethyl umbelliferone which is conveniently followed by its
emission at 450 nm (λex=360 nm). Due to potential issues
with compound interference this system is ideally per-
formed in a kinetic mode and should include a pre-read of
the ﬂuorescence following compound addition but before
addition of phosphatase enzyme.
Other ATP-dependent enzymes
Bioluminescent ATP/ADP detection methods used for pro-
tein kinases are also useful for other classes such as lipid
kinases (Vidugiriene et al., 2009) and metabolic enzymes
such as hexokinase (EC 2.7.1.1) and pyruvate kinase (EC
2.7.1.40). For pyruvate kinase, ATP is the product of the
kinase reaction rather than the substrate (Inglese et al.,
2006). Pyruvate kinase, the M2 isoform being an important
target in cancer, has been screened using this approach
where potent activators and inhibitors of the enzyme have
been identiﬁed (Boxer et al., 2010; Jiang et al., 2010). Many
of the glycololytic enzymes can be assayed alone or in
combination using bioluminescent ATP or ADP detection.
ATP and ADP formation methods should be adaptable to
other enzyme classes such as phosphodiesterases, and
ATPases such as heat-shock proteins or polymerases.
Other nucleotide-dependent enzymes
The red shifted FP based system used for protein kinases
has also been expanded to an analogous antibody-based system
for detecting UDP which is useful for UDP-dependent glycosyl-
transferases (EC 2.4), AMP/GMP for PDEs and ligases (EC 6).
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2002; Eglen and Singh, 2003). Additionally, following the
principles described for kinase activity detection, the system
of labeled substrate and polyarginine coupled with FP detec-
tion can be utilized for cAMP and cGMP phosphodiesterases
where the hydrolytic opening of the cyclic phosphate is
accompanied by an increase in the net negative charge.
DNA replication
A general, inexpensive, and simple method to conﬁgure assays
for polymerase and reverse transcriptases was reported over
10 years ago by Seville et al. (1996). The authors used the
exquisite speciﬁcity of Pico Green towards double-stranded
DNA and DNA–RNA hybrids where binding of the dye to the
strands leads to a dramatically enhanced ﬂuorescence,
(λex=480 nm, λem=520 nm). Thus, Pico Green detects the
presence of DNA–DNA or DNA–RNA double-stranded products
but remains non-ﬂuorescent in the presence of single-stranded
substrate and primer(s). The assay is performed as an end-
point read, after the addition of Pico Green solution containing
EDTA to stop the reaction (S:B410-fold). The same publica-
tion, exhibited measurement of polymerization in a kinetic
mode. Another approach uses labeled oligonucleotides which
form a hairpin structure bringing the 5' and 3' ends of the
oligonucleotide together which results in either ﬂuorescent
quenching or a FRET signal. This so called “molecular beacon”
approach (Figure 7) has been used to measure DNA ligase and
polymerase activity (Liu et al., 2005).
Oxidoreductases and redox enzymes
One of the most important enzymes in drug discovery efforts is
the class of oxidoreductases known as the cytochrome P450
(CYP) family (most of which have been classiﬁed as unspeciﬁc
monooxygenases, (EC 1.14.14.1)). Two cell-free HTS assay
systems are available for this class of enzymes (Zlokarnik
et al., 2005). One system employs ﬂuorescence-based detec-
tion of pro-ﬂuorescent substrates for speciﬁc CYP isoforms
(Crespi et al., 2002) and the other employs pro-luminescentFigure 7 Molecular Beacon approach for polymerases. An oligonuc
sequence. In the example shown, a ﬂourophore is placed on the 30
short primer to the loop region, a polymerase can be added with nu
ﬂuorescence quenching.substrates for CYPs using derivatives of D-luciferin that prevent
its recognition by ﬁreﬂy luciferase (Sobel et al., 2007). In the
luminescent assay the CYPs convert a pro-luciferin substrate
to D-luciferin allowing bioluminescent detection through ﬁreﬂy
luciferase (Cali et al., 2006; Auld et al., 2013). The kinetic
values of the substrates used in both systems have been well
characterized, allowing for estimation of Ki values. Considera-
tion of CYP substrate selectivity is an essential issue if the
source of enzyme is from liver microsomes (Foti and
Wahlstrom, 2008). While both systems mentioned above
measure product formation, the luminescent system detects
product through coupling to luciferase and must be performed
as an endpoint assay. A disadvantage of the ﬂuorescent system
is that the compound ﬂuorescence may interfere, however the
assay can be performed kinetically which can minimize such
interferences. A similar luminescent based system for mono-
amine oxidase has also been described (Zhou et al., 2006).
For other families of oxidoreductases relatively few
choices for HTS assays exist. Oxidoreductases which utilize
either reduced or oxidized forms of nicotinamide as a
cofactor can be assayed conveniently by following the
increase or decrease in signal due to the ﬂuorescence of
reduced product, NADH or NADPH. While the oxidized
forms of these co-factors are “dark” and absorb weakly in
the UV range, their reduced counterparts both absorb
340 nm light with extinction coefﬁcients of over 6000 M1
cm1 and ﬂuoresce at 450 nm. For example, hydroxysteroid
dehydrogenase-catalyzed oxidation of estradiol can be
measured by monitoring the increase in ﬂuorescence inten-
sity associated with the conversion of NAD to NADH.
Because the ﬂuorescence generated from NADH/NADPH is
not very strong, compound ﬂuorescence will interfere with
this mode of detection. Therefore, it is recommended that
these assays are performed in a kinetic mode to increase
the S:B and reduce compound interference. Coupling to
diaphorase in the presence of resazurin (7-hydroxy-3H-
phenoxazin-3-one 10-oxide) yields formation of resoruﬁn
which ﬂuoresces at 590 nm, a region where ﬂuorescent
interference by LMW compounds is minimized. While this
red-shifted reporting system is signiﬁcantly less susceptible
to compound ﬂuorescence interference, it represents a lessleotide is designed to have a hairpin structure with a short stem
end and a quencher is placed on the 50 end. After annealing a
cleotides which results in unfolding of the hairpin and relieve of
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such is more cumbersome to optimize and has a more
limited dynamic range. Recently, a luminescent assay for
either NADH or NADPH based on the reduction of a pro-
luciferin substrate has been made available (Promega).
For redox enzymes that generate/consume H2O2, the
Amplex Red coupled assay is especially appropriate. In this
case, catalase and resazurin are added at the end of the
primary enzymatic reaction and the concentration of H2O2
can be measured via the generation of highly ﬂuorescent
resoruﬁn product (from the resazurin oxidation by H2O2).
For lipoxygenases, a chromogenic assay has been published
which can be used in HTS (Cho et al., 2006) – lipoxygenase-
catalyzed oxidation of linoleic or arachidonic acid substrate
leads to the formation of lipid a peroxide product. In acidic
pH conditions, this product can oxidize ferrous ions added at
the end of the enzymatic reaction and the ferric ions
generated in turn bind tightly to Xylenol Orange (absorption
maximum of 405 nm) to form an intensely-colored complex
with absorption maximum of 565 nm. The ﬁnal product
is stable over several hours, thus allowing batch-mode
screening. One concern with peroxide detection, or any
redox-based detection, is that certain compounds such as
pyrimidotriazinediones in the presence of strong reducing
reagents such as DTT will undergo a redox-cycling reaction
to generate H2O2 (see section “Common Assay Artifacts in
Biochemical Enzyme Assays”) (Bova et al., 2004). A facile
assay to check compounds for redox cycling involves simply
adding the compounds under consideration to a reaction
containing Amplex Red and horse-radish peroxidase alone
(Johnston et al., 2008).
The xylenol orange assay is an absorbance-based assay.
Absorbance based measurements are extremely sensitive to
bubbles and volume/meniscus variations. One approach to
enable highly miniaturized absorbance assays is to construct
the assay using an epi-absorbance read-out. This can be
achieved by using the intrinsic ﬂuorescence properties of
the plastic used to construct solid white microtiter plates
(Zuck et al., 2005). Quenching of plate ﬂuorescence by the
enzymatic product can provide a higher signal-to-
background as the both the quenching of the light through
the sample (either excitation or emission light) as well as
the light reﬂected off the plate plastic results in increased
path length in the sample. This mode of detection has been
used for inorganic phosphate detection derived from
enzyme assays with malachite green-based detection of
the free phosphate. In this case the white 1536-well plates
were excited at 530 nm and ﬂuorescence was measured at
630 nm – with phosphate production the malachite green
turns into a blue solution which absorbs the 630 nm light
emission light (Zuck et al., 2005).Proteases
Proteases are a well-established class of drug targets
(Leung et al., 2000) and have received considerable cover-
age in terms of assay formats and reagent kits. Proteases
are typically measured using a peptide labeled with a
FRET pair or a pro-ﬂuorescent substrate. The use of 5-
(2-aminoethyl)aminonaphthalene-1-sulphonyl (EDANS) and
4-(-4-dimethylaminophenylazo)benzoyl (DABCYL) has beenapplied to endoproteases using FRET for detection (λex=340
nm/λem=475 nm) but suffers from compound interference
and solubility issues. Another simpler ﬂuorogenic substrate
incorporates an aminomethyl coumarin (AMC) moiety at the
carboxy terminus of a short peptide. The AMC group is dark
when conjugated to the rest of the peptide but when
liberated as a result of protease-catalyzed hydrolysis,
exhibits strong ﬂuorescence in the UV region (λex=360 nm,
λem=450 nm). This approach is widely used to assay pro-
teases and has numerous advantages such as allowing real-
time monitoring of reaction progress. They are extremely
simple to conﬁgure as only one addition step is required to
start the reaction. The AMC-containing substrates are
generally stable, easy to synthesize, and widely available
in a variety of sequence contexts from different vendors. A
drawback of this approach is that the ﬂuorogenic substrate,
being an extremely truncated version of the biologically
relevant substrate, cannot serve as a probe for the entire
enzymatic pocket. As a number of studies aim to target
proteases' extended binding sites (Schechter and Berger,
1967), different types of substrates are being developed.
Primarily, these are longer peptides (7–12 amino acids long)
in which the scissile bond is around the middle of the
sequence. In order to generate a detectable signal, a FRET
donor pair is incorporated. While the use of such substrates
can potentially yield better-quality inhibitors, their design
and synthesis remains a trial-and-error process. In situations
where FRET-based substrate is inaccessible, separation
approaches, such as the “LabChip” microﬂuidic system from
Caliper and others, might be the best alternative. Another,
less frequently used form of a FP-based protease assay is the
application of a ﬂuorescein/biotin dual-labeled substrate.
In this format, the precise distance between ﬂuorescent
label and biotin is irrelevant as there is no FRET phenom-
enon. Upon cleavage, the ﬂuorescent label is separated
from the biotin tag. Addition of streptavidin to the reaction
mixture will lead to an increase in FP proportional to the
amount of remaining substrate.
While there are numerous ways to assay endoproteases,
assays for exoproteases that recognize carboxy or amino-
terminal residues are far less available. A HTRF assay for
carboxypeptidase B (EC 3.4.17.2) has been developed for
HTS where cleavage of a peptide unmasks an epitope which
is then recognized by an antibody (Ferrer et al., 2005).Histone deacetylases (HDACs)
HDACs (EC 3.5.1.98) have been assayed for a number of
years by radiometric measurements, after extraction of the
released acetic acid from hyperacetylated tritiated histone
substrate. In a surrogate assay, Schreiber's group (Kwon
et al., 1998) attached a coumarin label to a known HDAC
inhibitor, K-trap, and used the HDAC-labeled K-trap complex
to search for novel inhibitors, essentially converting the
enzymatic deacetylation reaction into a binding/displace-
ment type of assay. More recently, a commercial ﬂuorogenic
assay has become available. In the Fluor-de-Lys system from
Biomol, the lysine residue in the substrate is exposed upon
deacetylation and, during a development reaction, is con-
verted via proprietary reagent to a ﬂuorescent product. As
with any assay, interpretation of the results requires careful
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activators for the HDAC known as SIRT1 (Howitz et al., 2003;
Milne et al., 2007), that is compounds which appear to
increase the afﬁnity of SIRT1 for an acetylated p53-derived
peptide, was confounded by the ﬂuorescent tag used in the
Fluor-de-Lys system. The putative SIRT1 activators were
subsequently found to be inactive when a different label
was used in the assay or unlabeled peptides were employed
and products detected by either HPLC or release of [14C]-
nicotinamide (Kaeberlein et al., 2005; Pacholec et al.,
2010). This again illustrates the necessity to perform an
orthogonal assay (Thorne et al., 2010) – in this case the
same enzyme assay but with a different detection readout,
before interpreting results. Another suitable assay for SIRT1
which could serve as an orthogonal assay for the Fluor-de-
Lys assay employs pro-luciferin substrates and these assays
can be miniaturized to a 10 μL assay volume (Halley et al.,
2011). “Label-free” assays have been developed for HDACs
using LC/MS for detection of peptides of acetyl-CoA pro-
ducts (Rye et al., 2011). Additionally, similar to the use of
labeled ATP competitive inhibitors in protein kinases,
labeled inhibitors (either hydroxamates, benzamides, or
cyclic peptides) to Class I and IIb HDACs have been used in
displacement-binding assays for HDACs (see reference Marks
et al., 2011 and references therein).Histone methylases/demethylases
Regulation of gene expression by chromatin is in part regulated
by a class of enzymes which methylate or demethylate histone
proteins. The ﬁrst lysine speciﬁc histone demethylase discov-
ered is LSD1. This enzyme a member of the monoamine
oxygenase family (EC: 1.4.3.4) and catalyzes the demethylation
of mono- and di-methylated lysine through reduction of FAD.
The reaction proceeds through the formation of a positively
charged imine intermediate which degrades to produce for-
maldehyde and the amine. In this process FAD is reduced to
FADH2 which is subsequently reoxidized by molecular oxygen
with the production of hydrogen peroxide. Therefore a number
of enzymatic products are available and assays have been
developed using LC/MS to detect peptide product (Metzger
et al., 2010) and coupled enzymatic reactions have been used
to detect either hydrogen peroxide or formaldehyde (Forneris
et al., 2005). High-throughput mass spectrometry methods,
such as the RapidFire mass spectrometry system from Biotrove
(Hutchinson et al., 2012) can enable HTS on libraries as large as
200 K in size (Ozbal et al., 2004; Roddy et al., 2007). A TR-
FRET assay operating in a signal decrease mode, using an
antibody that recognizes H3K4me1 but not the unmethylated
product, has been recently described (Yu et al., 2012).
Additionally, an AlphaScreen-based assay has also been devel-
oped using an antibody to an H3K4me1 peptide (Gauthier et al.,
2012). A sensitive assay using TR-FRET-based detection of an
unmethylated histone-3 peptide by a ﬂuorescent europium-
chelate labeled monoclonal antibody which binds speciﬁcally to
the H3K4me0 site has been used in HTS (Wang et al., 2011). As
the antibody in this assay recognizes the unmethylated product,
an increase in signal upon LSD1 inhibition is obtained which is
more desirable than a signal decrease mode where compounds
which interfere with the signal would be detected.Generic assays for HMTs have also been developed. Some
HMTs that catalyze the transfer of a methyl group to either
lysine or arginine require the co-factor adenosyl-L-methio-
nine (SAM). A generic assay for this class methyl transferases
has been described (Ibanez et al., 2012). In this assay
biotinylated peptides are methylated with a [3H-Me]-SAM
cofactor and streptavidin-coated SPA beads are used for
detection. When histone H3 is employed as a common
substrate, this SPA format provides a generic read-out for
HMTs. Interestingly, a recent study on the HMT G9a showed
that HMT inhibitors can be uncompetitive inhibitors (versus
SAM), suggesting that this class of enzyme may be similar to
dehydrogenases where uncompetitive inhibitors (versus
nicotinamide co-factor) have been developed (Lin et al.,
2012). In this study mass spectrometry was applied to
detect the S-adenosylhomocysteine product (Lin et al.,
2012).
One of the largest classes of histone demethylases contain a
Jumonji C domain (JMJD) and members of this family are Fe2+
and 2-oxoglutarate-dependent oxygenases which demethylate
speciﬁc lysine residues of histone tails. The JMJD2 human
subfamily contains six members (JMJD2A-F). Assays for JMJD
demethylases have been developed to enable the discovery of
chemical probes which could be useful for validating the role of
these enzymes in disease. Like other demethlyases, the
Jumonji-demethylases produce formaldehyde and this bypro-
duct can be detected using formaldehyde dehydrogenase (FDH)
(Lizcano et al., 2000). Miniaturized ﬂuorescent assays (through
detection of the NADH produced by FDH) have been developed
and applied to HTS using this approach (King et al., 2010).
However, assays that are speciﬁc for the methyl mark are
desirable and TR-FRET-based assays have been developed using
antibodies that are speciﬁc for the ﬁrst demethylated product.
An assay using Eu-antiH3K9me2 has been used to measuring
demethylation of a H2K9me3 labeled peptide (Yu et al., 2012).
The RapidFire system has also been applied to JMJD2C where
the methylated products of a peptide were measured
(Hutchinson et al., 2012). The inherent basicity of histone
peptides can be an issue for MS due to the high number of
charged states but the JMJD2C assay was developed using a
truncated and mutated peptide with suitable performance on
the MS which also maintained similar kinetic parameters to the
native peptide.Ubiquitin proteases and ligases
Signaling pathways in cells are often controlled by the stability
and localization of proteins operating at critical nodes in the
pathway. Protein stability and localization can be regulated
through the conjugation of ubiquitin or ubiquitin-like proteins
to various protein targets. Both ubiquitin ligases and ubiquitin
speciﬁc proteases, known as deubiquitylases (DUBs) or ubiquitin
C-terminal hydrolases (UCHs) are involved in this regulation.
Dysregulation of the ubiquitin pathway has been associated
with a number of diseases and therefore several assays have
been developed for this class of enzymes. Coupled enzyme
assays have been developed for measurement of isopeptidase
activity of DUBs. These assays involve fusion of a ubiquitin chain
to the N-terminus of enzymes such as phospholipase A2 or
enterokinase which require a free N-terminus to be functional.
Cleavage of the ubiquitin chain by a DUB results in an active
Figure 8 Example modes of interference and methods to address these in enzyme assays. (A) Top, certain compounds form large
(4200 nm) colloidal aggregates which sequester the enzyme and prevent interaction with substrate leading to inhibition. Bottom, example
concentration–response curves for aggregating compounds often show steep Hill slopes and addition of non-ionic detergents above at
concentrations above the critical micelle concentration leads to relief of the inhibition through disruption of the colloidal particle. The
compound shown is PubChem CID:648705 found to be a promiscuous inhibitor in the cysteine protease Cruzain (PubChem AID:1476). (B) Top,
certain compounds such as quinolones undergo redox cycling in the presence of reducing reagents such as DTT via the mechanism shown.
This redox cycle generates hydrogen peroxide which can inactive the enzyme in the assay. Bottom, a simple test for redox cycling
compounds (RCCs) is to remove the DTTor replace DTTwith a less strong reducing reagent such as cysteine (Cys). If the compound is acting
as a RCC then the inhibition is relieved in the absence of DTT. The compound shown is PubChem CID: 647501, a RCC that generates peroxide
upon exposure to DTT (PubChem AIDs: 672, 878, 787, 1234, 2035; adopted from Thorne et al. (2010)). (C) Compounds can directly interfere
with the detection of the assay signal. Top, depicts an AlphaScreen assay where a biotinylated peptide substrate is used as substrate for a
kinase. Detection of phosphorylated peptide is enabled by adding streptavidin coated donor AlphaScreen beads (“D”) and phosphospeciﬁc
antibody and protein A coated AlphaScreen acceptor beads (“A”). Upon excitation of the donor bead with a laser light source singlet oxygen
is generated that results in a chemiluminescence signal emitted from the acceptor bead except in cases where compounds that react with
the singlet oxygen are present, or those that absorb the chemiluminescence signal. Bottom, a simple test for this interference is to compare
the IC50 of the compound in the optimized enzyme assay where the inhibitor is allowed to compete for free enzyme in the presence of
substrate to an assay where the inhibitor is added after the enzyme assay has been completed. If the IC50 curves closely match as in the
example shown then non-speciﬁc interference with assay signal is the mechanism of inhibition.
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substrate (Tian et al., 2011). Additionally, the use of different
reporter enzymes can enable multiplex assays where more than
one DUB activity is measured in the assay (Tian et al., 2011).
Suitable counter-screens against the coupling enzyme are
required before interpreting the results from these assays.
Ubiquitin ligase (EC 6.3.2.19) activity has been measured using
AlphaScreen (Eglen et al., 2008) in 1536-well microtiter plates
(Cassaday et al., 2007).Common assay artifacts in biochemical enzyme
assays
Ensuring that the enzyme assay is performed under acceptable
conditions of enzyme and substrate concentrations to make theassay sensitive to modulators of the enzyme activity is a
primary consideration for enzyme assays. However, there are
several artiﬁcial mechanisms by which compounds can interfere
with the enzyme assay (Thorne et al., 2010) and in many cases
there are methods to directly test for these interferences
(Figure 8). These include compound aggregation which
non-speciﬁcally inhibits the enzyme, enzyme inactivation
mediated by a by-product from the compound sample, and
direct interference with the assay signal (McGovern et al.,
2003). Compounds that aggregate to form large (4100 nm)
colloidal particles can sequester the target enzyme and prevent
interaction with the substrate leading to inhibition (Figure 8A).
These aggregates are not precipitates of the compound which
could be spotted by the presence of a “cloudy” solution, but
instead these are colloids which give the appearance of a clear
solution and therefore speciﬁc tests are required to detect the
Figure 9 (A) Schematic of the assay for the histone demethylase LSD1. The assays uses a TR-FRET format with an antibody that is
speciﬁc for the demethylated lysine 4 (K4) resulting in a signal increase upon demethylation. (B) The stepwise HTS protocol and
notes are shown for the LSD1 TR-FRET assay.
Source: Adapted from Wang et al. (2012).
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effect is that the inhibition is sensitive to non-ionic detergents
such as TWEEN or Triton (0.01–0.1% can relieve the inhibition)
the IC50 curves can show steep Hill slopes, and the IC50 varies
with enzyme concentration. As well, the same compounds
often inhibit a completely different enzyme with essentially
the same potency (β-lactamase has been used as a counter-
screen, Feng et al., 2007). Not all aggregates act the same way
with different enzymes so one needs to speciﬁcally test for this
mode of interference using the methods listed above. Recently,
a compound was identiﬁed in an HTS which activated
procaspase-3 and subsequent examination showed that the
nature of the activation was due the formation of a nanotube
by the compound which sequestered the proenzyme to the
surface, increasing the local concentration or possibly modifying
the conformation leading to activation (Zorn et al., 2011).
Certain compounds, for example ortho-quinones, in the
presence of common reducing reagents such as DTT can
undergo a redox reaction which leads to generation of
peroxide (Thorne et al., 2010) that inactivates the enzyme
(Figure 8B). The hallmark of this effect is that the inhibition
is relieved when the DTT concentration is reduced (o1 mM)
or removed from the assay or a weaker reducing reagent
such as Cys is used. A high-throughput colorimetric assay
using horse radish peroxidase has also been developed to
directly test for compounds which produce hydrogen per-
oxide through redox cycling (Johnston et al., 2008).
As mentioned brieﬂy above for the SPA format, some
compounds may absorb light at the wavelength in which the
assay signal is generated. In AlphaScreen, compounds that
absorb light in the 526–620 nm range or react with singlet
oxygen will interfere (Figure 8C) (Baell and Holloway, 2010).
For ﬂuorescent assays, more compound interference is
observed with blue ﬂuorescent dyes (e.g. coumarin) than
red ﬂuorescent dyes (e.g. TexasRed) as many LMW com-
pounds found in typical screening libraries do not show
ﬂuorescence beyond 550 nm (Simeonov et al., 2008). The
use of time-resolved-FRET (TR-FRET) can reduce compound
ﬂuorescence interference as ﬂuorescence by typical LMW
compounds has short ﬂuorescent life-times. Speciﬁc recom-
mendations have been described for setting-up TR-FRET
assays to reduce compound interference (Imbert et al.,2007). A number of different methods can be used to test
for compound interference in an enzyme assay. In one
method, the compound is added to the enzyme assay once
the reaction has progressed to near completion which tests
for compounds interfering with the assay signal (Figure 8C).
As mentioned throughout this review, another method
involves using an orthogonal assay design where the same
assay is performed but with a different detection technol-
ogy (Thorne et al., 2010).Reporting HTS enzyme assay protocols
A guideline for reporting HTS assay protocols has been
suggested (Inglese et al., 2007). We provide an example of this
format in Figure 9. In this case the critical liquid handling,
incubation, reagent additions, and detection steps are noted on
the top of the table with details provided at the bottom in the
table “Note” section. Speciﬁc details around, for example
substrate concentration relative to Km, can also be noted here
but should be detailed in the text of the manuscript following
the STRENDA guidelines (http:/www.beilstein-institut.de/en/
projects/strenda/guidelines/).Future of enzyme assays
Improvements in existing technologies include continuous
read enzyme assays and dual labels allowing the detection
of both substrate and product, as well as continue improve-
ment of LC/MS technology to allow rapid and sensitive
detection of products in a label-free mode. New detection
technologies that should minimize interference by test
compounds include ﬂuorescent lifetime (FLT) measurements
(Moger et al., 2006). Fluorescent lifetime assays exploit the
effect of nonradioactive decay mechanisms on the ﬂuor-
ophore's ﬂuorescent lifetime. Additionally, although not
covered in this review, there are an increasing number of
cell-based designs to measure compound binding or enzyme
inhibition in a cellular setting allowing for assaying enzymes
in the cellular milieu which should improve the physiological
relevance of the compounds uncovered.
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